| 产品详情 |
| Edit |   |
|---|
| Product Name | Midkine Inhibitor, iMDK |
|---|
| Description | Purity ~98% (HPLC). A cell-permeable imidazothiazolyl-chromenone compound that reduces cellular midkine/MDK protein level in H441 lung adenocarcinoma cells in a dose-dependent manner (by >90% in 48h at 25nM) via a yet unidentified mechanism. Shown to inhibit the viability of MDK-positive HEK293, H441, and H520 cells (by ≥60% at 500nM in 48h), but not MDK-negative NHLF or HEK293 (by <15% at 500nM in 48h), via apoptosis induction as a result of PI 3-K/AKT signaling inhibition. Intraperitoneal injection is reported to be efficacious in retarding H441 tumor expansion in mice (9mg/kg; 3X to 5X per wk) in vivo. Primary Target: Midkine Solubility: DMSO |
|---|
| Size | 10mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | Midkine Inhibitor, iMDK (MDK Expression Inhibitor, 3-(2-(4-Fluorobenzyl)imidazo[2,1-b]thiazol-6-yl)-2H-chromen-2-one, 3-(2-(4-Fluorobenzyl)imidazo[2,1-b][1,3]thiazol-6-yl)-2H-chromen-2-one) |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | 217548 |
|---|
| Price | |
|---|
| Order / More Info | Midkine Inhibitor, iMDK from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|